A mango-based food ingredient, for food supplements and functional foods, that helps maintaining a healthy metabolism and an optimal body composition while preventing glucose intolerance

Project Information

Care300

Grant agreement ID: 815776

DOI

10.3030/815776

Project closed

EC signature date 4 May 2018

Start date 1 May 2018

End date 31 August 2018

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

VITAL SOLUTIONS SWISS AG
Switzerland

Periodic Reporting for period 1 - Care300 (A mango-based food ingredient, for food supplements and functional foods, that helps maintaining a healthy metabolism and an optimal body composition while preventing glucose intolerance)

Reporting period: 2018-05-01 to 2018-08-31

Summary of the context and overall objectives of the project

The so-called ‘lifestyle related diseases” account nowadays for most of deaths and disabilities in the developing world. Unhealthy diets and low levels of physical activity are among the main risk factors for non-communicable diseases and syndromes such as obesity, diabetes and metabolic syndrome. Furthermore, they place a tremendous burden on healthcare systems (associated costs are 2.8% of the world’s GDP).
Being aware of the importance of improving the quality of human life by enabling people to feel better, age well and live longer, Vital Solution Swiss developed Care300, a novel 100% natural, mango-based ingredient for food supplements and functional foods, that keeps our metabolism healthy. With this project we aim to test and validate Care300 so to obtain an EFSA claim, to enhance our supply-chain and to develop an adapted and successful commercial strategy for the product.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During this FS we set up a draft study design for 2 human study protocols fulfilling EFSA requirements for showing effectiveness of Care300 in maintaining a healthy metabolism and to obtain an EFSA claim. We studied granted patents and ongoing patent applications like Care300 to prove its novelty and our freedom to operate. Our market study showed that Italy, Germany, UK, France and Spain are the most promising markets for Care300, where it will be sold as an ingredient to manufacturing companies of food supplements, directly or via distributors.
The comparison made of Care300 with current competitors showed that no similar products have the EFSA claim so far and no other products are as active as Care300 is on body composition.
We identified potential supply chain partners to ensure raw material availability and processing capacities to produce Care300 related to the business plan.
Moreover, by designing a dissemination campaign and using our distributors network we will increase the product visibility and gain market share globally.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The product innovation is the elaboration of a natural ingredient that stimulates the activation of master regulators of the metabolic processes, such as Sirtuin 1 and the Activated Protein Kinase. According to our forecast we estimate to reach a net profit of €5.858.423 and a cumulated profit of €17.118.679 by 2025, with a ROI of 5,7. We also expect the creation of 15 job positions in the company, mainly in marketing and sales areas, as well as in purchasing and general administration.

care300.png